Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases.The term was introduced in the inaugural Editorial,Introducing Oncotarget.
As of January 1, 2022,Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
SSP 47th Annual Meeting
Post-Publication Promotion
Learn about ourFREE
Impact Journals, LLC is the publisher of Oncotarget:www.impactjournals.com.
Impact Journals is a member of theWellcome Trust List of Compliant Publishers.
Impact Journals is a member of theSociety for Scholarly Publishing.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.This malicious action will be reported to the FBI.
Current Volume
This Month's Popular DOIs
(Crossref resolutions)
| 10.18632/ONCOTARGET.23208 |
| 10.18632/ONCOTARGET.6429 |
| 10.18632/ONCOTARGET.9859 |
| 10.18632/ONCOTARGET.13553 |
| 10.18632/ONCOTARGET.14401 |
| 10.18632/ONCOTARGET.15422 |
| 10.18632/ONCOTARGET.16407 |
| 10.18632/ONCOTARGET.19087 |
Most popular Oncotarget DOIs, measured by the number of times each DOI was successfully resolved.
Most Popular DOIs Published in 2024
(Crossref Data)
Top-10 Most Popular DOIs of 2024
(Crossref Data)
Milestones in Modern Scholarly Publishing
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025.Learn more here andhere.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds.Learn more.
Oncotarget.org: Blog Posts on
New & Trending Papers
Oncotarget.net: Latest Insights
From Our Authors
February 11, 2020
About The Cover
The cover for issue 6 of Oncotarget features Figure 3, "The effect of NCs treatments on routine lab results during disease and recovery progress," byBen-Nun-Shaul, et al.
Table of Contents
Research Papers
| Empty SV40 capsids increase survival of septic rats by eliciting numerous host signaling networks that participate in a number of systemic functions |
https://doi.org/10.18632/oncotarget.27448 Orly Ben-Nun-Shaul,Rohit Srivastava,Sharona Elgavish,Shashi Gandhi,Yuval Nevo,Hadar Benyamini,Arieh Eden, and Ariella Oppenheim |
| 574-588 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release | Podcast | Video Interview |
| Prognostic value of a three-scale grading system based on combining molecular imaging with68Ga-DOTATATE and18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias |
https://doi.org/10.18632/oncotarget.27460 Ioannis Karfis,Gwennaëlle Marin,Hugo Levillain,Stylianos Drisis,Raoul Muteganya,Gabriela Critchi,Loubna Taraji-Schiltz,Carlos Artigas Guix,Leila Shaza,Meriem Elbachiri,Laura Mans,Godelieve Machiels,Alain Hendlisz, and Patrick Flamen |
| 589-599 |
| Abstract | PDF | Full Text | How to cite |
| Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies |
https://doi.org/10.18632/oncotarget.27466 Richard K. Yang,Yun Qing,Fatima Zahra Jelloul,Mark J. Routbort,Peng Wang,Kenna Shaw,Jiexin Zhang,Jack Lee,L. Jeffrey Medeiros,Scott Kopetz,Michael T. Tetzlaff, and Russell R. Broaddus |
| 600-618 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release |
| In vitro studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy |
https://doi.org/10.18632/oncotarget.27478 Layla Al-mansoori,Sara S. Bashraheel,Alanod D. Al Qahtani,C. David O’Connor,Philip Elsinga, and Sayed K. Goda |
| 619-633 |
| Abstract | PDF | Full Text | How to cite | Press Release |
| Human insulin modulates α-synuclein aggregation via DAF-2/DAF-16 signalling pathway by antagonising DAF-2 receptor inC. elegans model of Parkinson’s disease |
https://doi.org/10.18632/oncotarget.27366 Rizwanul Haque, Shamsuzzama,Lalit Kumar,Tanuj Sharma,Soobiya Fatima,Pooja Jadiya,Mohammad I. Siddiqi, and Aamir Nazir |
| 634-649 |
| Abstract | PDF | Full Text | How to cite | Press Release |
Reviews
| Risk factors for breast cancer brain metastases: a systematic review |
https://doi.org/10.18632/oncotarget.27453 Lola Koniali,Andreas Hadjisavvas,Anastasia Constantinidou,Kyproula Christodoulou,Yiolanda Christou,Christiana Demetriou,Andreas S. Panayides,Constantinos Pitris,Constantinos S. Pattichis,Eleni Zamba-Papanicolaou, and Kyriacos Kyriacou |
| 650-669 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release |  |
Retraction
| Retraction: Neutrophil extracellular traps promote peritoneal metastasis of colon cancer cells |
https://doi.org/10.18632/oncotarget.27482 Amr A. Al-Haidari,Nader Algethami,Mattias Lepsenyi,Milladur Rahman,Ingvar Syk, and Henrik Thorlacius |
| 670-670 |
| Retraction | PDF | How to cite |
Copyright © 2025 Rapamycin Press LLC dba Impact Journals